CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts

CeriBell (NASDAQ:CBLL) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $32.60.

CBLL has been the topic of a number of research reports. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price on the stock. William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Canaccord Genuity Group raised their price objective on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 9th. Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock.

CeriBell Trading Up 9.0 %

CeriBell stock opened at $22.94 on Friday. CeriBell has a 52-week low of $18.69 and a 52-week high of $32.75. The business’s 50 day simple moving average is $26.02.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. Equities analysts expect that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.